Tempus Q3 2024 Results & Ambry Acquisition
Tempus AI, Inc. (NASDAQ: TEM), a technology company driving AI adoption in precision medicine and patient care, released its...
Tempus AI, Inc. (NASDAQ: TEM), a technology company driving AI adoption in precision medicine and patient care, released its...
Immunis, a clinical-stage biotech company, has launched non-terminal safety studies for canine muscle atrophy in partnership with VetBio Partners....
Enveric Biosciences, a biotechnology company focused on developing novel neuroplastogens for neuropsychiatric disorders, has significantly expanded its patent protection....
Vertex Pharmaceuticals reported strong third-quarter 2024 financial results and raised its full-year product revenue guidance. The company anticipates continued...
Allurion Technologies, a company focused on combating obesity, presented two abstracts at Obesity Week 2024. The first abstract showcased...
Scholar Rock, a late-stage biopharmaceutical company, has released promising preclinical data for SRK-439, an investigational anti-myostatin antibody. The data...
Medincell‘s long-acting injectable technology, BEPO®, has achieved commercial success with its first product, UZEDY® (risperidone LAI), for treating schizophrenia...
CinFina Pharma, a CinRx portfolio company focused on obesity treatments, has released promising interim data from a Phase 1...
Hedonia, a mobile mental health solutions provider, has released promising findings from a recent economic model. The study, conducted...
Fulgent Genetics, a technology-driven company specializing in laboratory services and therapeutic development, secured a five-year contract with the U.S....